Antibodies Prevent HIV Infection in Monkeys

Infusing anti-HIV antibodies provides macaques with protection against infection for up to six months, according to a study.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

HIV-infected T cellFLICKR, NIAIDWith a successful HIV vaccine still proving elusive, researchers have proposed antibody injections as possible short-term protection against the virus. Previous work has demonstrated that treating mice or macaques with anti-HIV antibodies can protect the animals against subsequent high-dose challenges with HIV or related viruses. Scientists from the National Institute of Allergy and Infectious Diseases (NIAID) and their colleagues have now shown that such protection may last for six months or more. After receiving a single injection of one of four broadly neutralizing HIV antibodies, macaques were able to withstand weekly low-dose challenges of a simian/human (SIV/HIV) chimeric virus for three to six months, according to a study published this week (April 27) in Nature.

“The result is surprising,” Ruth Ruprecht, who directs the AIDS Research Program at Texas Biomedical Research Institute and was not involved in the study, told The Verge. “I am astonished by how long protection lasted.”

“A caveat is that monkeys are not humans, but the model the authors use is about as good as it gets, and the results are a boost to HIV vaccine research and the use of passive antibodies as long-acting preventives,” Scripps Research Institute immunologist Dennis Burton, who was not involved with the work, told Nature. Moreover, added study coauthor Malcolm Martin of NIAID, “this might turn out to be a seasonal alternative to a vaccine until we really know how to make one.”

Such antibody treatments could also one day ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours